Erba, H. P., Fathi, A. T., Issa, G. C., Altman, J. K., Montesinos, P., Patnaik, M. M., … Wang, E. S. (2022). Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. In Blood (Vol. 140, pp. 153–156). American Society of Hematology. https://doi.org/10.1182/blood-2022-167412

Erba, Harry P., Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, et al. “Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” In Blood, 140:153–56. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-167412.

Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, et al. Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. In: Blood. American Society of Hematology; 2022. p. 153–6.

Erba, Harry P., et al. “Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 153–56. Crossref, doi:10.1182/blood-2022-167412.

Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, Foran JM, De Botton S, Baer MR, Schiller GJ, Walter RB, Kremyanskaya M, Pettit KM, Strickland SA, Tomkinson B, Tabachri M, Leoni M, Dale S, Wang ES. Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. American Society of Hematology; 2022. p. 153–156.